Navigation Links
Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
Date:4/4/2011

HOPKINTON, Mass., April 4, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the launch of XenoLight(TM) RediJect(TM) COX-2 Probe (Fluorocoxibs), a novel fluorescent imaging agent for pre-clinical research that specifically detects the cyclooxygenase-2 (COX-2) biomarker noninvasively in live animal models as well as in ex vivo tissue analysis applications. The COX-2 fluorescent probe technology was invented at the research laboratory of Dr. Lawrence Marnett at Vanderbilt University and is licensed to Caliper.

"COX-2 is over-expressed in a variety of inflammatory and neoplastic diseases.  The opportunity to non-invasively image COX-2 offers promise for both the early detection of disease and monitoring therapeutic response.  The fluorocoxib probe should be valuable to investigators in multiple disciplines, including cancer research," said Professor Andrew Dannenberg, Director of Cancer Center at Weill Cornell Medical College, a research leader in the field of COX-2 in oncology and inflammation.

Researchers can gain an understanding of therapeutic efficacy in specific patient populations by monitoring key biomarker response to a drug treatment.  These findings then help tailor patient-specific therapeutic strategies to improve outcomes and advance the scope of personalized medicine.  For example, COX-2 detection in tumors has become an important tool in predicting the outcome of various chemotherapy treatments, including advanced lung cancer.  Caliper's RediJect COX-2 probe provides the ability to non-invasively detect COX-2 in early-stage cancer cells, with a level of sensitivity and accuracy not attainable by conventional methods.  

"Personalized therapies to treat specific patient populations are becoming reality," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. "Our partnership with Professor Lawrence Marnett, the inventor of the COX-2 probe and a prolific author and thought leader in the field, will further catalyze research in biomarker response, helping to provide insight into the development of new or rescued targeted therapies.  Caliper remains committed to providing translational research technology and services focused on further realizing the full potential of personalized medicine."

The RediJect COX-2 probe is the latest in an expanding range of reagents for Caliper's IVIS® and Maestro® optical imaging systems, and our Trio(TM), Nuance® and Vectra® tissue analysis systems. Caliper's portfolio of industry-leading pre-clinical imaging technology complements an expansive range of imaging reagents optimized to enable researchers to monitor various biological events, in live models and in excised tissue samples.  Caliper offers a variety of fluorescent and bioluminescent reagents that can be applied in a range of therapeutic areas, including oncology, infectious diseases, inflammation, neurology and stem cell research.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to develop life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results that translate into potential cures for a range of diseases. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.

Caliper and IVIS are registered trademarks, and XenoLight and RediJect are trademarks, of Caliper Life Sciences, Inc.  Maestro, Nuance and Vectra are registered trademarks, and Trio is a trademark, of Cambridge Research and Instruments, Inc., a wholly owned subsidiary of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
2. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
3. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
4. Caliper Awarded New Task Order for EPA ToxCast Program
5. Caliper Life Sciences Introduces Sciclone(R) G3 Liquid Handler
6. Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research
7. Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic
8. Caliper Life Sciences Forms Scientific Advisory Board for Next Generation Sequencing
9. Caliper Life Sciences Fourth Quarter 2009 Financial Results Conference Call Notice
10. Caliper Life Sciences and Stanford University File a Patent Infringement Lawsuit Against Carestream Health, Inc.
11. Caliper Settles Outstanding Litigation with Shimadzu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies ... Fibromyalgia market. The research answers the following questions: ... and their clinical attributes? How are they positioned in the Global ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An ... true account of his paramedic experiences. Schanssema describes the tragedies he saw, as well ... to overcome them. , Schanssema, initially unsure of the career path he wanted to ...
(Date:2/24/2017)... ... 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer ... started as the Chairman of the Management Committee when IFN was originally formed in ... recruitment of investor/owners and development of the business plan. He became the first ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... official 2017 partnership with The Jensie Gran Fondo of Marin. For the second ... rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our ...
(Date:2/23/2017)... ... 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce ... a longtime supporter of the event. , "We are pleased that KLS Martin is ... Havlik, 2017 ACPA President. "KLS Martin has a long track record of support of ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April ... diverse symposium on “Doping in Sport: How the Culture Might Change,” ... Hampton LLP. The symposium will be held at Pepperdine University in Malibu, California. ...
Breaking Medicine News(10 mins):